Last updated: September 12, 2026
Tomivosertib, also known as eFT508, is an oral, selective mitogen-activated protein kinase-interacting kinase 1 and 2 inhibitor developed by Effector Therapeutics. The program was evaluated primarily with pembrolizumab in advanced non-small-cell lung cancer and other solid tumors. The drug has no FDA approval, no commercial revenue, and no Orange Book listing. Its near-term commercial value is limited because clinical development has not produced a validated registration path.
What is the current development status of tomivosertib?
Tomivosertib is an investigational oral immuno-oncology drug targeting MNK1 and MNK2. These kinases regulate phosphorylation of eukaryotic initiation factor 4E, or eIF4E, a pathway involved in protein translation, tumor-cell survival, and immune resistance.
| Attribute |
Status |
| Generic name |
Tomivosertib |
| Development code |
eFT508 |
| Developer |
Effector Therapeutics |
| Mechanism |
Selective MNK1/MNK2 inhibition |
| Modality |
Oral small molecule |
| Lead combination |
Pembrolizumab |
| Principal disease focus |
Advanced solid tumors, including NSCLC |
| FDA approval |
None |
| FDA breakthrough or accelerated approval |
None publicly established |
| Orange Book listing |
None |
| Commercial revenue |
None |
| Biosimilar relevance |
Not applicable |
The principal clinical rationale was that MNK inhibition could increase antitumor immune activity and improve response to PD-1 blockade. Tomivosertib was therefore developed mainly as a combination therapy rather than as a standalone cytotoxic or targeted treatment.
Which clinical trials evaluated tomivosertib?
The most important study was the KICKSTART trial, a Phase 2b study of tomivosertib plus pembrolizumab in patients with advanced or metastatic non-small-cell lung cancer. The study was designed to test whether adding tomivosertib could improve outcomes in patients whose tumors had progressed after prior treatment.
Clinical development also included earlier Phase 1 and Phase 1/2 studies in advanced solid tumors. These studies assessed safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity.
Key clinical-development timeline
| Period |
Development event |
| 2016-2018 |
Early clinical evaluation of eFT508 begins in advanced solid tumors |
| 2019-2021 |
Combination development with pembrolizumab expands |
| 2021-2022 |
Effector advances the KICKSTART Phase 2b program in NSCLC |
| 2022-2023 |
KICKSTART generates clinical efficacy data for the tomivosertib-pembrolizumab combination |
| 2023-2024 |
The program’s development priority declines after the company’s clinical and strategic reprioritization |
| As of the latest broadly available public information |
No pivotal registration trial or FDA submission has been disclosed |
ClinicalTrials.gov lists the tomivosertib studies and provides the most direct record of trial design, enrollment, endpoints, and study status. The KICKSTART program was the central test of whether the mechanism could produce a commercially meaningful benefit in a defined cancer population. [1]
Did tomivosertib meet its clinical objectives?
The program did not establish a clear registration-quality efficacy profile. Early studies showed that tomivosertib could be administered in combination with pembrolizumab, but tolerability and preliminary activity were not sufficient to create an obvious path to approval.
The key commercial issue is not whether isolated responses occurred. It is whether the combination demonstrated a reproducible benefit against an active comparator or a clinically accepted benchmark in a sufficiently large population. Public development activity did not progress to a disclosed Phase 3 program or a regulatory filing.
The absence of a pivotal trial has several consequences:
- No established approval probability based on confirmatory data.
- No validated biomarker strategy.
- No demonstrated survival advantage in a commercially defined NSCLC segment.
- No basis for a near-term launch forecast.
- Reduced strategic value for a pharmaceutical partner.
What is the FDA and Orange Book status of tomivosertib?
Tomivosertib is not FDA-approved. It therefore has no approved label, no FDA-recognized indication, and no Orange Book-listed patents.
The Orange Book generally lists patents associated with approved drug products and their approved uses. Because tomivosertib has not received FDA approval, there is no Orange Book patent-exclusivity framework comparable to that for marketed small-molecule drugs such as osimertinib, pembrolizumab, or nivolumab. [2]
| Regulatory issue |
Tomivosertib status |
| New Drug Application |
No publicly disclosed approval |
| Biologics License Application |
Not applicable |
| Approved indication |
None |
| Orange Book product |
None |
| Hatch-Waxman Paragraph IV exposure |
Not yet commercially operative |
| New chemical entity exclusivity |
Not granted |
| Pediatric exclusivity |
None publicly identified |
| Marketed drug exclusivity |
None |
If development resumes and Effector or a licensee files an NDA, the company would need to establish the relevant patent and regulatory exclusivity position at that time. Current development status does not provide an immediate generic-entry timetable.
What patents protect tomivosertib?
Tomivosertib is a small molecule, so its potential protection would normally involve several patent categories:
- Composition-of-matter patents covering tomivosertib and related MNK inhibitors.
- Pharmaceutical-composition patents covering dosage forms and excipients.
- Method-of-treatment patents covering MNK inhibition in cancer.
- Combination-treatment patents covering tomivosertib with PD-1 or PD-L1 inhibitors.
- Manufacturing patents covering intermediates, synthetic routes, or purification methods.
Effector has publicly described intellectual-property protection for its MNK inhibitor platform. Public company disclosures indicate that the patent estate was intended to extend into the 2030s, subject to jurisdiction, patent-term adjustment, patent-term extension, maintenance, and claim validity. [3]
A precise freedom-to-operate and expiry analysis requires a family-by-family review of issued claims, continuations, terminal disclaimers, national-phase prosecution, and patent-term calculations. The absence of an approved product also means there is no single Orange Book patent date that can be used as the commercial loss-of-exclusivity date.
How strong is the tomivosertib patent estate?
The estate has moderate theoretical value but weak standalone commercial value under the current clinical profile.
| Patent-value factor |
Assessment |
| Composition-of-matter protection |
Potentially the strongest category |
| Platform breadth |
Could cover multiple MNK inhibitors, but breadth depends on issued claim scope |
| Combination patents |
Potentially useful against PD-1 combinations, but dependent on clinical and label relevance |
| Formulation patents |
Secondary importance for an oral small molecule |
| Manufacturing patents |
May raise process barriers but rarely supports premium valuation alone |
| Patent expiry |
Likely extends into the 2030s for some families, based on company disclosures |
| Litigation value |
Limited without an approved commercial product |
| Licensing value |
Dependent mainly on clinical validation |
Composition claims can retain value after clinical setbacks if they cover a differentiated molecule and competing MNK inhibitors require the same chemical space. Method-of-use patents are less valuable if the clinical indication lacks efficacy data or if a future label does not include the patented use.
When does tomivosertib lose exclusivity?
There is no fixed U.S. loss-of-exclusivity date because tomivosertib has not been approved.
Public disclosures indicate that certain patent rights were expected to remain in force into the 2030s. That does not establish a single product-level expiry date. The effective exclusivity period would depend on:
- Which composition patent claims survive prosecution or litigation.
- Whether continuation applications issue.
- Patent-term adjustment.
- Potential patent-term extension after FDA approval.
- The scope of any approved indication.
- The existence of alternative MNK1/MNK2 compounds.
- Regulatory exclusivity granted with an eventual NDA.
A generic applicant cannot make a standard commercial Paragraph IV launch calculation until an approved reference product and Orange Book listings exist.
Are there Paragraph IV challenges or patent litigation involving tomivosertib?
No material public Paragraph IV challenge has been identified. That result is consistent with the absence of an FDA-approved tomivosertib product.
No major public U.S. patent litigation involving a generic challenger and a marketed tomivosertib product has been disclosed. Any future litigation would likely arise from one of three situations:
- An ANDA filer challenges composition claims after approval.
- A competitor develops a chemically distinct MNK inhibitor.
- A licensee attempts to enforce combination or method-of-use claims against an oncology competitor.
The absence of litigation should not be interpreted as proof that the patents are invalid or weak. It primarily reflects the program’s precommercial status.
What licensing deals affect tomivosertib?
Effector has been the principal publicly identified developer of tomivosertib. No major disclosed transaction has established a global commercial partner with responsibility for late-stage development, regulatory filing, or commercialization.
That limits the program’s current value in business-development markets. Large pharmaceutical companies typically require a clear clinical signal, a defined biomarker strategy, or a differentiated mechanism before assuming the cost of a global oncology development program. Tomivosertib has not publicly reached that threshold.
Potential transaction structures would likely involve one of the following:
| Deal structure |
Commercial rationale |
| Regional license |
Limits partner risk while testing a specific market |
| Option-to-license |
Defers commitment until new biomarker or combination data |
| Asset sale |
Transfers development cost and residual patent value |
| Combination partnership |
Links tomivosertib to an immunotherapy or targeted agent |
| Platform license |
Monetizes MNK-related intellectual property rather than the molecule alone |
How does tomivosertib compare with competing immuno-oncology drugs?
Tomivosertib competes indirectly with approved checkpoint inhibitors and directly with experimental agents designed to reverse resistance to PD-1 or PD-L1 therapy.
| Program type |
Clinical maturity |
Commercial position |
| Pembrolizumab and nivolumab |
Approved, multibillion-dollar markets |
Strong |
| Small-molecule immune-resistance agents |
Mixed, mostly clinical-stage |
Unproven |
| MNK1/MNK2 inhibitors |
Early or limited clinical validation |
Weak to developing |
| Tomivosertib plus pembrolizumab |
No approval, no pivotal program |
High risk |
| Novel targeted combinations |
Varies by biomarker and disease |
Competitive |
Tomivosertib’s main differentiation is its oral mechanism and potential to affect both tumor-cell translation and the immune microenvironment. Its main weakness is the lack of a proven population in which MNK inhibition adds sufficient benefit to established checkpoint therapy.
What is the market projection for tomivosertib?
Tomivosertib has no current market and no base-case launch date. A commercially credible forecast must therefore use scenario analysis rather than a conventional launch model.
Tomivosertib market scenarios
| Scenario |
Probability view |
Potential launch timing |
Peak annual sales |
| No further development |
Highest |
None |
$0 |
| Partnered restart in a biomarker-defined NSCLC population |
Low |
2030 or later |
$50 million-$150 million |
| Successful development in NSCLC plus additional solid tumors |
Very low |
2030 or later |
$200 million-$500 million |
| Broad immuno-oncology adoption |
Remote |
2030 or later |
Above $500 million |
These are analytical scenarios, not company guidance.
A successful product would need to enter a market dominated by pembrolizumab-based regimens, competing checkpoint combinations, antibody-drug conjugates, KRAS-directed therapies, and other immune-resistance programs. Pricing could support substantial revenue only if tomivosertib produced a clinically meaningful improvement in response duration, progression-free survival, or overall survival.
A reasonable risk-adjusted valuation framework is:
- Current product revenue: $0.
- Near-term commercial probability: low.
- Probability of reaching a pivotal trial: limited without a new sponsor or clinical thesis.
- Probability of approval from the current development position: very low.
- Risk-adjusted peak sales: likely below $50 million absent new positive data.
- Unrisked peak sales: potentially $200 million-$500 million if a responsive population is identified.
What generic launch risks exist for tomivosertib?
Generic launch risk is currently theoretical because no reference product is approved. If tomivosertib eventually reaches the market, risk would depend on the surviving composition claims and the approved label.
The principal risks would include:
- ANDA challenges to composition patents.
- Patent litigation before commercial launch.
- Use of different solid forms or salts.
- Alternative manufacturing routes.
- Narrow method-of-use claims that do not block all oncology use.
- Off-label use outside patented indications.
- Competing MNK inhibitors with non-infringing structures.
The strongest barrier would be a valid, enforceable composition-of-matter patent covering the marketed molecule. Formulation and manufacturing patents would provide less durable protection unless the product depended on a technically difficult delivery system or a narrowly claimed process.
What is the investment outlook for tomivosertib?
Tomivosertib is best valued as a dormant or low-priority clinical asset with residual intellectual-property value, not as a near-term commercial oncology product.
The investment case would improve materially only if a sponsor demonstrates one of the following:
- A reproducible response signal in a biomarker-defined population.
- Positive survival data in combination with an established checkpoint inhibitor.
- A mechanistic rationale for selecting patients with high eIF4E activity or immune resistance.
- A partner willing to fund a pivotal trial.
- A differentiated combination that avoids direct competition with entrenched PD-1 regimens.
Without those developments, the program’s value is primarily optionality around its MNK inhibitor patents and any future use in combination therapy.
Key Takeaways
- Tomivosertib is an oral MNK1/MNK2 inhibitor developed by Effector Therapeutics.
- Its principal clinical program combined tomivosertib with pembrolizumab in advanced NSCLC.
- The drug has no FDA approval, no Orange Book listing, and no commercial revenue.
- No standard Paragraph IV or generic-entry timetable currently applies.
- Public disclosures indicate patent protection extending into the 2030s for parts of the program, but no single U.S. product expiry date exists.
- The absence of a pivotal registration program makes near-term approval unlikely.
- The base-case market projection is $0 without renewed development.
- A successful biomarker-driven relaunch could support approximately $50 million-$150 million in peak sales, while broad adoption could produce higher revenue but remains remote.
FAQs
Is tomivosertib still being actively developed?
Publicly available development activity has not established an active late-stage program. The drug has not advanced to a disclosed Phase 3 registration trial or FDA filing.
Is tomivosertib a chemotherapy drug?
No. Tomivosertib is an oral targeted small molecule that inhibits MNK1 and MNK2. It was developed primarily for use with pembrolizumab rather than as conventional chemotherapy.
Could tomivosertib be approved for lung cancer?
Approval would require new clinical development, a defined target population, and evidence from an adequately controlled trial. No approval pathway has been established.
Does tomivosertib have biosimilar competition?
No. Biosimilars apply to biological products. Tomivosertib is a small molecule, so any future competition would involve generic or follow-on small-molecule products.
What would make tomivosertib commercially attractive again?
A validated biomarker, positive combination data, a clear survival benefit, and a development partner would be the most important value drivers. Without those elements, patent protection alone is unlikely to support a large commercial valuation.
References
- ClinicalTrials.gov. (n.d.). Study of eFT508 in patients with advanced solid tumors and in combination with pembrolizumab. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Effector Therapeutics, Inc. (2023). Annual report on Form 10-K. U.S. Securities and Exchange Commission.